NSCLC patients with high neoplastic ICAM-1 expression and serum soluble ICAM-1 levels show more aggressive lung cancer progression [4–6], suggesting a potential role of ICAM-1 in promoting NSCLC. This evidence concerns the gene ICAM1 and non-small cell lung carcinoma.